13 Oct Registration Open for 2nd Annual Drug Pricing Policy Summit
On November 15 & 16, 2017 from 8:30 a.m. – 5:00 p.m., you are invited to join the Canadian Cancer Survivor Network, Schizophrenia Society of Ontario, Save Your Skin Foundation, and other patient groups for the second annual Drug Pricing Policy Summit in Toronto, Ontario.
This year’s Summit will build on the inaugural 2016 Summit with updates from across the regulatory, public and private policy environments. In addition, the 2017 Summit will present different views on drug pricing policy in Canada, including perspectives on value-based healthcare with a focus on patient outcomes and putting the patient at the centre of the process. Panelists will include leaders in the public and private payer environments, pharmaceutical industry and prescribers.
To read more about the background information, visit the Canadian Cancer Survivor Network website for the following links and more:
Click here to view a description of bodies involved in drug pricing policy in Canada.
Join us for the following webinars detailing updates on the climate of drug pricing policy in Canada as we approach this year’s Summit:
October 18, 2017, 12-1pm EDT – pan-Canadian Public Health Systems : The Basics
Presenters: Wayne Critchley, Louise Binder
This webinar will provide a broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada, describing the legal framework, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement. This is a primer for attendees attending the November 15-16, 2017 Drug Pricing Policy Summit and for others who would like to have a review of these systems for their interest.
November 1, 2017, 12-1pm EDT – Health Technology Assessment : What does value really mean for public drug plans?
Presenter: Matthew Brougham
This webinar will describe the process used by nine provinces and the territories to assess the value of a drug in determining whether public drugs plans should reimburse the drug through their plans. This is called a health technology assessment. It will describe the role and methodology of the Canadian Agency for Drugs and Technologies in Health in leading this assessment for both oncology and non-oncology drugs.